Related Experiment Video
Updated: Nov 23, 2025

05:44
Author Spotlight: Developing Acetyl-Click Assay for HAT1 Inhibitor Screening
Published on: January 26, 2024
1.1K
Harnessing Ionic Selectivity in Acetyltransferase Chemoproteomic Probes
Yihang Jing1, Jose L Montano1, Michaella Levy2
1Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
ACS Chemical Biology
|December 29, 2020
Summary
This study introduces a new chemical proteomics strategy using coenzyme A (CoA) probes to improve enzyme inhibitor selectivity. The method enhances probe optimization and background signal differentiation for better therapeutic agent discovery.
Area of Science:
- Chemical proteomics
- Biochemistry
- Drug discovery
Background:
- Chemical proteomics is vital for enzyme function and inhibitor selectivity studies.
- Optimizing chemical probes and reducing background noise are key challenges.
- Coenzyme A (CoA) is a crucial cofactor in many enzymatic reactions.
Purpose of the Study:
- To develop a physiochemical discernment strategy for optimizing chemical proteomics probes.
- To differentiate probe capture properties based on subtle chemical modifications.
- To evaluate the selectivity of small molecule N-terminal acetyltransferase inhibitors.
Main Methods:
- Synthesis of CoA-based sepharose pulldown resins with distinct charge properties.
- Integration of probes with quantitative proteomics and gel-based profiling.
- Benchmarking probe selectivity analysis against traditional competitive chemical proteomics.
Main Results:
- A single charged residue difference significantly altered resin capture properties.
- Probe selectivity analysis is effective for identifying optimized pulldown probes.
- Anionic CoA probes successfully evaluated N-terminal acetyltransferase inhibitor selectivity.
Conclusions:
- Physicochemical discriminant strategies enhance chemoproteomic hit identification.
- CoA-based probes are valuable for assessing small molecule inhibitor selectivity.
- This approach aids in the development of novel therapeutic agents targeting protein acetyltransferases.

